Common use of IMMEDIATE ATTENTION REQUIRED Clause in Contracts

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “Purchasers”) electing to purchase shares of Common Stock (“Common Stock”) of ViewRay Incorporated (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and each of those persons and entities listed as a Purchaser on Annex A thereto (the “Purchase Agreement”) to which this Questionnaire is an Annex. This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-1 being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Purchaser in order to include such Purchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx & Xxxxxxx 000 Xxxxx Xxxxx Menlo Park, CA 94025 Attn: Fax: (000) 000-0000 xxxxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx at: (650) 463-xxxx.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “Purchasers”) electing to purchase shares of Common Stock (“Common Stock”) of ViewRay Corcept Therapeutics Incorporated (the “Company”) pursuant to the Securities Purchase Agreement Agreement, made as of [ ], 2009, by and among the Company and each of those persons and entities listed as a Purchaser on Annex A thereto (the “Purchase Agreement”) to which this Questionnaire is an AnnexPurchasers. This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-1 S-3 being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into Agreement, made as of [ ], 2009, by and among the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase Agreement). The Company must receive a completed Questionnaire from each Purchaser in order to include such Purchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx & Xxxxxxx 000 Xxxxx Xxxxx Menlo ParkXxxxxxxxxx Xx., Suite 2000 San Francisco, CA 94025 94109 Attn: Xxxxx Ing Fax: (000) 000-0000 xxxxx@xx.xxx xxxxx.xxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx Xxxxx Ing at: (650000) 463000-xxxx0000.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the any such person or entity a “PurchasersPurchaser”) electing to purchase shares of Common Series A Convertible Preferred Stock (“Common Preferred Stock”) of ViewRay Incorporated Cxxx.xxx, Inc. (the “Company”) pursuant to the Securities Purchase Investment Agreement by and among between the Company and each of those persons and entities listed as a Purchaser on Annex A thereto (the “Purchase Agreement”) Google Capital 2016, L.P. to which this Questionnaire is an AnnexAppendix. The Preferred Stock is convertible into shares of the Company’s Common Stock (“Common Stock”). This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-1 S-3 being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Investor Rights Agreement entered into by and among the Company and the Purchasers Google Capital 2016, L.P. (the “Registration Investor Rights Agreement”) in connection with the Purchase Investment Agreement. The Company must receive a completed Questionnaire from each the Purchaser in order to include such Purchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers are the Purchaser is advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx Lxxxxx & Xxxxxxx 000 Wxxxxxx LLP 500 Xxxxxxxx Xxxxxx, XX Xxxxx Xxxxx Menlo Park0000 Xxxxxxxxxx, CA 94025 X.X. 00000-0000 Attn: Jxxx Xxx Fax: (000) 000-0000 xxxxx@xx.xxx jxxx.xxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx Jxxx Xxx at: (650000) 463000-xxxx0000. PART I - STOCK OWNERSHIP Item 1. Beneficial Ownership.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “PurchasersSelling Stockholders”) electing receiving or anticipated to purchase receive shares of Common Stock common stock, par value $0.001 per share (“Common Stock”) of ViewRay Incorporated Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”) pursuant ), issued or anticipated to be issued by the Securities Company to Tripex Pharmaceuticals, LLC, a Delaware limited liability company (“Tripex”), in accordance with that certain Asset Purchase Agreement by and among the Company and each of those persons and entities listed (as a Purchaser on Annex A thereto (such agreement may be amended from time to time, the “Purchase Agreement”) ), dated as of August 20, 2015, by and between the Company and Tripex, including pursuant to which this Questionnaire is an Annexany distribution from Tripex of such shares of Common Stock. This Questionnaire relates to certain information required to be disclosed in the Registration Statement a registration statement on Form S-1 S-3 being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SECCommission”) pursuant to the Registration Rights Agreement Agreement, dated as of August 20, 2015, entered into by and among between the Company persons identified on the signature pages thereto and each person who shall join pursuant to the Purchasers terms thereof (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Purchaser Selling Stockholder in order to include such PurchaserSelling Stockholder’s shares of Common Stock in the Registration Statementregistration statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement registration statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers the Selling Stockholders are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement registration statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx & Xxxxxxx LLP 000 Xxxx Xxxxxx Xxxxx, 00xx Xxxxx Xxxxx Menlo ParkXxxx, CA 94025 Xxxxxxxxxx 00000 Attn: Xxxx Xxxxxx Fax: (000###) 000###-0000 xxxxx@xx.xxx #### ####### Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx Xxxx Xxxxxx at: (650000) 463000-xxxx0000.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “Purchasers”) electing to purchase shares of Common Stock (“Common Stock”) of ViewRay Incorporated Tokai Pharmaceuticals, Inc. (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and each of those persons and entities listed as a Purchaser on Annex A thereto the Purchasers (the “Purchase Agreement”) to which this Questionnaire is an AnnexAppendix. This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-1 S-3 (the “Registration Statement”) being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Purchaser in order to include such Purchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx & Xxxxxxx 000 Xxxxx Xxxxx Menlo Park, CA 94025 Attn: Fax: (000) 000-0000 xxxxx@xx.xxx [●] Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx at: (650) 463-xxxx[●] at [●] or [●].

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “PurchasersInvestors”) electing to purchase include shares of Common Stock (“Insmed Common Stock”) of ViewRay Incorporated Insmed Incorporated. (the “CompanyInsmed”) pursuant to the Securities Purchase Agreement held by and among the Company and each of those persons and entities listed as them or issuable in connection with a Purchaser on Annex A thereto (the “Purchase Agreement”) to which this Questionnaire is an Annexwarrant. This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-1 S-3 (the “Form S-3”) being prepared by the Company Insmed for filing with the United States Securities and Exchange Commission (the “SEC”) by each of the Investors who wishes to sell Insmed Common Stock pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase AgreementForm S-3. The Company We must receive a completed Questionnaire from each Purchaser stockholder in order to include such Purchaserstockholder’s shares of Insmed Common Stock in for registration on the Registration StatementForm S-3. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement Form S-3 can result in potential liabilities, both civil and criminal, to the Company Insmed and to the individuals who furnish the information. Accordingly, Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or facsimile and overnight courier as soon as possible. Xxxxx, Xxxxxxx & Xxxxxxxxx, LLP 000 Xxxx Xxxxxx & Xxxxxxx 000 Xxxxx Xxxxx Menlo ParkXxxxxx, CA 94025 Xxxxxxxxxxxxx 00000 Attn: FaxXxxxxx Xxxxx-Xxxxx Facsimile Number: (000) -000-0000 xxxxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx at: (650) 463Xxxxxx Xxxxx-xxxxXxxxx at 000-000-0000.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “PurchasersInvestors”) electing to purchase shares of Common Stock ordinary shares, nominal value $0.00003881 per share (“Common StockOrdinary Shares”) ), of ViewRay Incorporated MeiraGTx Holdings plc, a Cayman Islands exempted company (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and each of those persons and entities listed as a Purchaser on Annex A thereto the Investors (the “Purchase Agreement”) to which this Questionnaire is an AnnexAppendix. This Questionnaire relates to certain information required to be disclosed in the registration statement (the “Registration Statement on Form S-1 being Statement”) to be prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers Investors (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Purchaser Investor in order to include such PurchaserInvestor’s shares of Common Stock Ordinary Shares in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers Investors are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx & Xxxxxxx LLP 000 Xxxxx Xxxxx Menlo ParkXxxxxx Xxx Xxxx, CA 94025 XX 00000-0000 Attn: Xxxxx Xxxxxx Fax: (000) 000-0000 xxxxx@xx.xxx 000.000.0000 xxxxx.xxxxxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx at: (650) 463-xxxxXxxx Xxxxxx at 000.000.0000 or xxxx.xxxxxx@xx.xxx or N. Xxxxx Xxxxxxx at 212.906.4797 or x.xxxxx.xxxxxxx@xx.xxx.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “PurchasersInvestors”) electing to purchase shares of Common Stock common stock, par value $0.001 per share (the “Common Stock”) (and/or pre-funded warrants to purchase shares of ViewRay Incorporated Common Stock), and Common Stock purchase warrants to purchase shares of Common Stock of Lyra Therapeutics, Inc. (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and each of those persons and entities listed as a Purchaser on Annex A thereto the Investors (the “Purchase Agreement”) to which this Questionnaire is an AnnexAppendix. This Questionnaire relates to certain information required to be disclosed in the registration statement (the “Registration Statement on Form S-1 Statement”) being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers Investors (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Purchaser Investor in order to include such PurchaserInvestor’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers Investors are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx & Xxxxxxx LLP 000 Xxxxxxxxx Xxxxxx, 00xx Xxxxx Xxxxx Menlo ParkBoston, CA 94025 MA 02116 Attn: Xxxxxxx X. Xxxxxxxx Fax: (000) 000-0000 xxxxx@xx.xxx E-mail: xxxx.xxxxxxxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx at: Xxxxxx X. Xxxxx at (650000) 463000-xxxx0000 or xxxxxx.xxxxx@xx.xxx.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “Purchasers”) electing to purchase shares of Common Stock (“Common Stock”) of ViewRay Incorporated Ardelyx, Inc. (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and each of those persons and entities listed as a Purchaser on Annex A thereto the Purchasers (the “Purchase Agreement”) to which this Questionnaire is an AnnexAppendix. This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-1 S-3 (the “Registration Statement”) being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Purchaser in order to include such Purchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. Xxxxxx & Xxxxxxx 000 Xxxxx Xxxxx Menlo Park, CA 94025 Attn: Xxxxxxxxx Xxxxx Fax: (000) 000-0000 xxxxx@xx.xxx xxxxxxxxx.xxxxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx at: Xxxxxxxxx Xxxxx at (650000) 463000-xxxx0000 or xxxxxxxxx.xxxxx@xx.xxx.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “PurchasersInvestors”) electing to purchase include shares of Common Stock (“XXXX Common Stock”) of ViewRay Incorporated XXXX Medical Systems, Inc. (the “CompanyXXXX”) pursuant to the Securities Purchase Agreement held by and among the Company and each of those persons and entities listed as them or issuable in connection with a Purchaser on Annex A thereto (the “Purchase Agreement”) to which this Questionnaire is an Annexwarrant. This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-1 S-3 (the “Form S-3”) being prepared by the Company XXXX for filing with the United States Securities and Exchange Commission (the “SEC”) by each of the Investors who wishes to sell XXXX Common Stock pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase AgreementForm S-3. The Company We must receive a completed Questionnaire from each Purchaser stockholder in order to include such Purchaserstockholder’s shares of XXXX Common Stock in for registration on the Registration StatementForm S-3. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement Form S-3 can result in potential liabilities, both civil and criminal, to the Company XXXX and to the individuals who furnish the information. Accordingly, Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please complete, sign sign, and return one copy of this Questionnaire by facsimile, email or facsimile and overnight courier as soon as possible. Xxxxxx Xxxxxx White & Xxxxxxx 000 XxXxxxxxx LLP 0000 Xxxx Xxxx Xxxx Xxxxx Xxxxx Menlo ParkXxxx, CA 94025 XX 00000 Attn: FaxK. Amar Murugan Facsimile Number: (000) 000-0000 xxxxx@xx.xxx Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact xxxxx at: K. Amar Murugan at (650000) 463000-xxxx0000.